Drugs / Delta24-RGD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01582516 | Jun 2010 → Dec 2014 | brain neoplasm, glioblastoma | Erasmus Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delta-24-rgd | “Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma” NCT01582516 ↗1“testing the oncolytic adenovirus Delta24-RGD to treat glioblastoma patients.” NCT01582516 ↗ |
| Known as | delta-24-RGD adenovirus | “delta-24-RGD adenovirus” NCT01582516 ↗ |
| Route | Other | “Intracerebral slow continuous infusion of study drug in increasing dose” NCT01582516 ↗ |